Glofitamab as a single agent in patients with relapsed/refractory mantle cell lymphoma

This study is evaluating a new treatment option for patients with mantle cell lymphoma, a type of blood cancer that has returned or has not responded to previous therapies. The goal is to see how well the treatment works compared to current standard options.

• Adults 18+ years of age
• Confirmed diagnosis of mantle cell lymphoma that has come back or did not respond to prior treatment
• Previously received at least one line of systemic therapy and still have measurable disease that can be evaluated on scans.
• Have adequate bone marrow, liver, and kidney function, as shown by blood tests.
• Must be well enough overall to carry out daily activities with limited restriction.

• Receiving the investigational treatment for mantle cell lymphoma through regular intravenous (IV) infusions on a scheduled cycle.
• Regular clinic visits for safety checks, which may include physical exams, blood tests, and heart monitoring (such as ECGs).
• Imaging scans will also be done periodically to see how the cancer is responding to the treatment.